Wygoda Zbigniew, Oczko-Wojciechowska Małgorzata, Gubała Elzbieta, Pawlaczek Agnieszka, Kula Dorota, Wiench Małgorzata, Włoch Jan
Department of Nuclear Medicine and Endocrine Oncology, Comprehensive Cancer Center and M. Sklodowska-Curie Memorial Institute of Oncology, Gliwice Branch, Gliwice.
Endokrynol Pol. 2006 Jul-Aug;57(4):407-14.
The assessment of frequency and type of mutation and differences in prognosis between sporadic and hereditary type of medullary thyroid carcinoma (MTC), based on own DNA analysis, was performed.
The group of 190 persons with hereditary MTC or asymptomatic mutation carriers was analyzed. Patients with sporadic MTC without RET gene mutation were included into control group (708 persons). The recognition of MTC type was based on assessment of family history, physical examination and genetic analysis. The family history consisted of information about MTC, pheochromocytoma and other neoplasms and hyperparathyroidism in relatives.
The mutations located in codon 634 of exon 11 were the most often (43% of all mutations and 49% of mutations in syndrome MEN 2A/FMTC). The age of diagnosis was ranged between 7 and 71 years (mean age: 39 +/- 15.2 years, median age: 41 years). In hereditary MTC the mean age of diagnosis was 27 +/- 13.9 years and was significantly lower than in sporadic one, where it was 45.7 +/- 14.3 years. The relationship between diagnosis, age and subtypes of hereditary MTC was assessed--no significant differences in examined subgroups were observed. The mean age of diagnosis in MEN 2A/FMTC and MEN 2A syndrome was 28-29 years, in MEN 2B - 21 years. The overall survival in sporadic MTC after 5 years was 97%, in hereditary MTC - 79%. Analysis performed after excluding suprarenal causes of death revealed no statistically significant differences in overall survival between both subtypes of MTC.
基于自身DNA分析,对散发性和遗传性甲状腺髓样癌(MTC)的突变频率、类型以及预后差异进行了评估。
对190例遗传性MTC患者或无症状突变携带者进行了分析。散发性MTC且无RET基因突变的患者被纳入对照组(708例)。MTC类型的识别基于家族史、体格检查和基因分析。家族史包括亲属中MTC、嗜铬细胞瘤及其他肿瘤和甲状旁腺功能亢进的信息。
位于第11外显子密码子634的突变最为常见(占所有突变的43%,在MEN 2A/FMTC综合征的突变中占49%)。诊断年龄在7至71岁之间(平均年龄:39±15.2岁,中位年龄:41岁)。遗传性MTC的平均诊断年龄为27±13.9岁,显著低于散发性MTC的45.7±14.3岁。评估了遗传性MTC的诊断、年龄与亚型之间的关系,在所检查的亚组中未观察到显著差异。MEN 2A/FMTC和MEN 2A综合征的平均诊断年龄为28 - 29岁,MEN 2B为21岁。散发性MTC 5年后的总生存率为97%,遗传性MTC为79%。排除肾上腺死因后进行的分析显示,两种亚型MTC的总生存率无统计学显著差异。